All In Biotech

Drug Trial Radar · NCT03509831

[KJ-INT-002] BE Study

A Randomized, Open-label, Crossover Clinical Study to Assess the Safety and the Pharmacokinetic Characteristics of INT-2150 After Oral Administration to Healthy Adult Male Subjects

Last checked: Nov 20, 2026Latest source record: Apr 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

37

Actual

Start

Nov 2, 2017

Primary completion

Jan 24, 2018

Study completion Apr 2018

Sponsor

Lead sponsor
Kukje PharmaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 19 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Assess the Safety and the Pharmacokinetic Characteristics of INT-2150 after Oral Administration to Healthy Adult Male Subjects

Conditions

  • Gastritis

Interventions

  • INT-2150Drug

    1. Period: INT-2150 2. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg

  • Irsogladine maleate 2 mg+Nizatidine 150 mgDrug

    1. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg 2. Period: INT-2150

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUCtTime frame: One day
  2. CmaxTime frame: One day

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kukje Pharm

    Seongnam-si, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.